Orforglipron is a new oral GLP-1 drug with 79% bioavailability and no food restrictions, outperforming injectable liraglutide in head-to-head trials.
79% bioavailabilityOrforglipron achieves high oral absorption without food or water restrictions
What the researchers found
Orforglipron 36 mg proved superior to injectable liraglutide in head-to-head Phase 3 trials with ~79% oral bioavailability and no dosing restrictions.
Why it matters
Many patients avoid GLP-1 drugs because of injections or oral semaglutide's strict fasting requirements — orforglipron removes both barriers.
The numbers in context
Orforglipron ~79% oral bioavailability. ACHIEVE-3: HbA1c -2.2% vs -1.4% (oral semaglutide 14 mg). Weight -9.2% vs -5.3%. No food/water restrictions. cAMP stimulation without beta-arrestin recruitment.
How the study worked
Review of pharmacology, pharmacokinetics, and Phase 3 clinical trial data (including ACHIEVE-3 head-to-head trial).
Who was studied
Adults with T2D and/or obesity
What this study cannot tell us
Review article — long-term safety and real-world effectiveness data are still emerging. Phase 3 trials have limited follow-up.
How to read the evidence
Review of Phase 3 trial data — strong clinical evidence, though the drug is not yet widely approved.
When this study was published
Published in 2025, covering the latest Phase 3 trial results for this emerging medication.
The bigger picture
If approved, orforglipron could dramatically expand GLP-1 drug access by eliminating the injection barrier that deters millions of potential patients.
Questions still open
- How does orforglipron compare head-to-head with injectable semaglutide?
- Will the lack of β-arrestin recruitment translate to sustained long-term efficacy?
Common questions
What makes orforglipron different from oral semaglutide?
Is orforglipron better than injectable GLP-1 drugs?
Read the original research
Orforglipron: A Novel Oral GLP-1 Agonist for the Treatment of Obesity and Diabetes.
Cardiology in review
Citation
Pillai, Ashwin A; Sharma, Ashish M; Krayem, Hussein; Frishman, William H; Aronow, Wilbert S. (2025). Orforglipron: A Novel Oral GLP-1 Agonist for the Treatment of Obesity and Diabetes.. Cardiology in review. https://doi.org/10.1097/CRD.0000000000001139